Tag
Laurus Labs Limited
5 articles
Laurus Labs' strong financial performance and strategic investments highlight its evolving business model. First-quarter results revealed a substantial 126% surge in net profit, driven by a 29% increase in revenue and significant EBITDA margin expansion fueled by CDMO growth and operational efficiencies. The company is further solidifying its position in the contract development and manufacturing organization (CDMO) space, diversifying its revenue streams and reducing reliance on its ARV business. A significant investment of ₹1,078 crore in KRKA Pharma underscores Laurus Labs’ commitment to partnerships and expansion, while a CARE ESG Level 1 rating reflects a leadership position in environmental, social, and governance practices.
Laurus Labs Assigned CARE ESG Level 1 Rating
Laurus Labs Limited disclosed its ESG rating of CARE ESG Level 1 with a score of 78/100, assigned by CARE ESG Ratings Limited.
The rating signifies a leadership position in managing ESG risk through b
Laurus Labs Invests ₹1,078 Cr in KRKA Pharma
Laurus Labs invested ₹1,078 million in KRKA Pharma via rights issue acquiring 107.8 million shares.
Post-investment, Laurus Labs maintains 49% stake in the joint venture with KRKA d.d., Slovenia.
Disc
Laurus Labs Q2 & H1 FY27 Earnings Conference Call
Laurus Labs will host an earnings conference call on October 29, 2026, to discuss its Q2 and H1 FY27 financial results.
The call, hosted by DAM Capital Advisors, will include a presentation of results
Laurus Labs Board Meeting for Q2 FY27 Results
Laurus Labs board to meet on October 29, 2026, to approve Q2 FY27 unaudited financial results.
Board will consider a proposal for an interim dividend payment for FY 2026-27 and fix a record date.
The
Laurus Labs Q1 Net Profit Surges 126%
Laurus Labs reported Q1 FY27 revenue of ₹2,026 Cr, up 29% YoY, with net profit surging 126% to ₹368 Cr.
EBITDA margins expanded 700 bps to 31.8% on strong CDMO growth and operational leverage improvem